High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1372349.
- Also identified by PMC identifier 488936.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.
Medical subject headings
- Antiviral Agents
- Myositis
- gamma-Globulins